增强血管植入物用氨酸-聚氨酸-铜纳米酶涂层用于协同抗凝和抗活动
Zheng Zeng1, Tao Liu2, Peiying Zeng3
1The Fourth Affiliated Hospital, School of Biomedical Engineering, Guangzhou Medical University, Guangzhou 511436, China; Key Laboratory of Advanced Technology of Materials, Ministry of Education, Southwest Jiaotong University, Chengdu 610031, China.
International journal of biological macromolecules
|April 11, 2025
概括
这项研究开发了一种用于血管植入物的新型纳米酶涂层,可以预防血栓并促进愈合. 先进的支架涂层有效地减少了血栓形成和缩,提高了心血管植入物安全性.
科学领域:
- 生物材料科学 生物材料科学
- 心血管工程 心血管工程
- 纳米技术纳米技术
背景情况:
- 像支架一样的血管植入物面临着诸如晚期支架血栓形成 (LST) 和支架静止 (ISR) 等挑战.
- 目前用于增强支架表面的策略通常是复杂的,旨在具有抗凝固剂,亲内皮质化和抗新极限增生症 (NIH) 特性.
- 在支架表面上实现多种功能通常需要复杂的修改.
研究的目的:
- 开发用于血管植入物的多功能纳米酶涂层.
- 创建一种涂层,提供抗凝活性和持续的氧化物 (NO) 在现场释放.
- 通过预防血栓形成和促进血管愈合,提高心血管植入物的安全性和有效性.
主要方法:
- 纳米酶颗粒使用氨酸,聚氨酸 (PLL) 和铜离子进行合成,用于催化氧化 (NO) 释放.
- 在多多巴胺 (PDA) 过渡层上对血管植入物施加功能性涂层.
- 为了评估涂层的性能,进行了体外,体外和体内研究.
主要成果:
- 纳米酶涂层表现出强大的抗凝剂活性,显著抑制血小板聚合并延长激活部分血栓形成时间 (APTT).
- 实现了持续的现场NO释放,促进了内皮细胞在光滑肌肉细胞上增长.
- 活体外和体内模型证实了优异的抗血栓疗效,增强了内皮再生,并抑制了NIH.
结论:
- 开发的纳米酶涂层为改善血管植入物性能提供了一个有前途的多功能解决方案.
- 这项技术通过结合抗凝剂和再生性质,有效地解决了像LST和ISR这样的关键挑战.
- 这些发现表明,心血管植入物的安全性和长期结果有很大的潜力.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
552
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
552
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
405
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
405
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.0K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.0K
Clot Retraction and Fibrinolysis
3.0K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
3.0K


